ROIV

SEC source: 0001140361-25-045279 · form4.xml · nonDerivative · entry 1

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,697,908

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-25-043203 · form4.xml · nonDerivative · entry 1

Pulik Richard · CIK 0001885841 · CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 388,273

F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

SEC source: 0001140361-25-043201 · form4.xml · nonDerivative · entry 1

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,497,908

F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.

SEC source: 0001193125-25-291731 · ownership.xml · nonDerivative · entry 4

Gold Daniel Allen · CIK 0001832142 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd.

Disclosed balance after: 18,047,727

F1 · ownership.direct: The reporting person is one of three directors of QVT Financial Investment Cayman Ltd. ("QVT FIC"), sharing voting and investment control over the Common Shares held directly by QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.

SEC source: 0001193125-25-291731 · ownership.xml · nonDerivative · entry 3

Gold Daniel Allen · CIK 0001832142 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd.

Disclosed balance after: 18,222,727

F1 · ownership.direct: The reporting person is one of three directors of QVT Financial Investment Cayman Ltd. ("QVT FIC"), sharing voting and investment control over the Common Shares held directly by QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.

SEC source: 0001193125-25-291731 · ownership.xml · nonDerivative · entry 2

Gold Daniel Allen · CIK 0001832142 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd.

Disclosed balance after: 18,347,727

F1 · ownership.direct: The reporting person is one of three directors of QVT Financial Investment Cayman Ltd. ("QVT FIC"), sharing voting and investment control over the Common Shares held directly by QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.

SEC source: 0001193125-25-291731 · ownership.xml · nonDerivative · entry 1

Gold Daniel Allen · CIK 0001832142 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd.

Disclosed balance after: 18,497,727

F1 · ownership.direct: The reporting person is one of three directors of QVT Financial Investment Cayman Ltd. ("QVT FIC"), sharing voting and investment control over the Common Shares held directly by QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.

SEC source: 0001193125-25-291734 · ownership.xml · nonDerivative · entry 4

MANCHESTER KEITH S · CIK 0001244828 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd.

Disclosed balance after: 18,047,727

F1 · ownership.direct: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.

SEC source: 0001193125-25-291734 · ownership.xml · nonDerivative · entry 3

MANCHESTER KEITH S · CIK 0001244828 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd.

Disclosed balance after: 18,222,727

F1 · ownership.direct: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.

SEC source: 0001193125-25-291734 · ownership.xml · nonDerivative · entry 2

MANCHESTER KEITH S · CIK 0001244828 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd.

Disclosed balance after: 18,347,727

F1 · ownership.direct: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.

SEC source: 0001193125-25-291734 · ownership.xml · nonDerivative · entry 1

MANCHESTER KEITH S · CIK 0001244828 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd.

Disclosed balance after: 18,497,727

F1 · ownership.direct: The reporting person is a shareholder of QVT Financial Investment Cayman Ltd. ("QVT FIC") but does not have any voting or investment control over QVT FIC. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.

SEC source: 0001193125-25-291727 · ownership.xml · nonDerivative · entry 4

QVT Financial LP · CIK 0001290162 · Director by Deputization

10b5-1 filing: No plan indicated

Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd.

Disclosed balance after: 18,047,727

F1 · ownership.direct: Aggregately, following the transactions described above, QVT Financial LP ("QVT"), a Delaware limited partnership, may be deemed to be the beneficial owner of 28,081,635 Common Shares, consisting of the Common Shares owned by QVT P&E Roiv Hldgs Ltd. ("QVT P&E"), QVT Deferred Compensation Holdings Ltd ("QVT DCH") and QVT Financial Investment Cayman Ltd. ("QVT FIC"). QVT Financial GP LLC ("QVT Financial GP"), a Delaware limited liability company, is the general partner of QVT and may be deemed to beneficially own the same number of Common Shares reported by QVT.

F2 · ownership.nature: QVT provides certain investment advisory services for, and thereby may be deemed to beneficially own the Common Shares held by, QVT P&E, QVT DCH and QVT FIC. QVT disclaims beneficial ownership of such Common Shares, except to the extent of any pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.

SEC source: 0001193125-25-291727 · ownership.xml · nonDerivative · entry 3

QVT Financial LP · CIK 0001290162 · Director by Deputization

10b5-1 filing: No plan indicated

Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd.

Disclosed balance after: 18,222,727

F1 · ownership.direct: Aggregately, following the transactions described above, QVT Financial LP ("QVT"), a Delaware limited partnership, may be deemed to be the beneficial owner of 28,081,635 Common Shares, consisting of the Common Shares owned by QVT P&E Roiv Hldgs Ltd. ("QVT P&E"), QVT Deferred Compensation Holdings Ltd ("QVT DCH") and QVT Financial Investment Cayman Ltd. ("QVT FIC"). QVT Financial GP LLC ("QVT Financial GP"), a Delaware limited liability company, is the general partner of QVT and may be deemed to beneficially own the same number of Common Shares reported by QVT.

F2 · ownership.nature: QVT provides certain investment advisory services for, and thereby may be deemed to beneficially own the Common Shares held by, QVT P&E, QVT DCH and QVT FIC. QVT disclaims beneficial ownership of such Common Shares, except to the extent of any pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.

SEC source: 0001193125-25-291727 · ownership.xml · nonDerivative · entry 2

QVT Financial LP · CIK 0001290162 · Director by Deputization

10b5-1 filing: No plan indicated

Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd.

Disclosed balance after: 18,347,727

F1 · ownership.direct: Aggregately, following the transactions described above, QVT Financial LP ("QVT"), a Delaware limited partnership, may be deemed to be the beneficial owner of 28,081,635 Common Shares, consisting of the Common Shares owned by QVT P&E Roiv Hldgs Ltd. ("QVT P&E"), QVT Deferred Compensation Holdings Ltd ("QVT DCH") and QVT Financial Investment Cayman Ltd. ("QVT FIC"). QVT Financial GP LLC ("QVT Financial GP"), a Delaware limited liability company, is the general partner of QVT and may be deemed to beneficially own the same number of Common Shares reported by QVT.

F2 · ownership.nature: QVT provides certain investment advisory services for, and thereby may be deemed to beneficially own the Common Shares held by, QVT P&E, QVT DCH and QVT FIC. QVT disclaims beneficial ownership of such Common Shares, except to the extent of any pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.

SEC source: 0001193125-25-291727 · ownership.xml · nonDerivative · entry 1

QVT Financial LP · CIK 0001290162 · Director by Deputization

10b5-1 filing: No plan indicated

Ownership: Indirect · Held by QVT Financial Investment Cayman Ltd.

Disclosed balance after: 18,497,727

F1 · ownership.direct: Aggregately, following the transactions described above, QVT Financial LP ("QVT"), a Delaware limited partnership, may be deemed to be the beneficial owner of 28,081,635 Common Shares, consisting of the Common Shares owned by QVT P&E Roiv Hldgs Ltd. ("QVT P&E"), QVT Deferred Compensation Holdings Ltd ("QVT DCH") and QVT Financial Investment Cayman Ltd. ("QVT FIC"). QVT Financial GP LLC ("QVT Financial GP"), a Delaware limited liability company, is the general partner of QVT and may be deemed to beneficially own the same number of Common Shares reported by QVT.

F2 · ownership.nature: QVT provides certain investment advisory services for, and thereby may be deemed to beneficially own the Common Shares held by, QVT P&E, QVT DCH and QVT FIC. QVT disclaims beneficial ownership of such Common Shares, except to the extent of any pecuniary interest therein, and the inclusion of these Common Shares in this report shall not be deemed an admission of beneficial ownership of all of the reported Common Shares for purposes of Section 16 or for any other purpose.

SEC source: 0001635075-25-000005 · primary_doc.xml · nonDerivative · entry 3

Ramaswamy Vivek · CIK 0001635075 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,653,756

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.20 to $20.72, inclusive.

SEC source: 0001635075-25-000005 · primary_doc.xml · nonDerivative · entry 2

Ramaswamy Vivek · CIK 0001635075 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,193,406

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $21.11, inclusive.

SEC source: 0001635075-25-000005 · primary_doc.xml · nonDerivative · entry 1

Ramaswamy Vivek · CIK 0001635075 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,221,076

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.54 to $21.08, inclusive. The reporting person undertakes to provide to Roivant Sciences Ltd., any security holder of Roivant Sciences Ltd., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), and (3) to this Form 4.

SEC source: 0001140361-25-041214 · form4.xml · derivative · entry 3

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,076,523

Underlying: Common Stock · 200,000 shares

Expires 2032-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).

SEC source: 0001140361-25-041214 · form4.xml · nonDerivative · entry 2

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,504,959

F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.

SEC source: 0001140361-25-041214 · form4.xml · nonDerivative · entry 1

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,704,959

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-25-038997 · form4.xml · nonDerivative · entry 1

Epperly Melissa B, · CIK 0001807359 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,904

F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

SEC source: 0001140361-25-038995 · form4.xml · nonDerivative · entry 2

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 118,388

F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.

SEC source: 0001140361-25-038995 · form4.xml · nonDerivative · entry 1

Oren Ilan · CIK 0001643073 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 118,669

F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

SEC source: 0001140361-25-038996 · form4.xml · nonDerivative · entry 2

MOMTAZEE JAMES C · CIK 0001209181 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,543

F2 · shares: Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.

SEC source: 0001140361-25-038996 · form4.xml · nonDerivative · entry 1

MOMTAZEE JAMES C · CIK 0001209181 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,701

F1 · shares: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

F1 · price: Reflects an award of Common Shares received pursuant to the Issuer's Non-Employee Director Compensation Plan that was fully vested as of the grant date.

SEC source: 0001140361-25-038545 · form4.xml · derivative · entry 9

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 118,418 shares

Expires 2026-03-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options are fully vested.

SEC source: 0001140361-25-038545 · form4.xml · nonDerivative · entry 6

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,504,959

F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.

SEC source: 0001140361-25-038545 · form4.xml · nonDerivative · entry 5

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,623,377

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-25-038545 · form4.xml · derivative · entry 8

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 118,418

Underlying: Common Stock · 318,282 shares

Expires 2026-03-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options are fully vested.

SEC source: 0001140361-25-038545 · form4.xml · nonDerivative · entry 4

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,504,959

F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.

SEC source: 0001140361-25-038545 · form4.xml · nonDerivative · entry 3

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,823,241

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-25-038545 · form4.xml · derivative · entry 7

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 436,700

Underlying: Common Stock · 414,683 shares

Expires 2026-03-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options are fully vested.

SEC source: 0001140361-25-038545 · form4.xml · nonDerivative · entry 2

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,504,959

F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.

SEC source: 0001140361-25-038545 · form4.xml · nonDerivative · entry 1

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,919,642

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-25-038126 · form4.xml · derivative · entry 6

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 851,383

Underlying: Common Stock · 20,727 shares

Expires 2026-03-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options are fully vested.

SEC source: 0001140361-25-038126 · form4.xml · nonDerivative · entry 4

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,504,959

F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.

SEC source: 0001140361-25-038126 · form4.xml · nonDerivative · entry 3

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,525,686

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-25-038126 · form4.xml · derivative · entry 5

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 872,110

Underlying: Common Stock · 104,940 shares

Expires 2026-03-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options are fully vested.

SEC source: 0001140361-25-038126 · form4.xml · nonDerivative · entry 2

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,504,959

F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.

SEC source: 0001140361-25-038126 · form4.xml · nonDerivative · entry 1

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,609,899

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-25-037740 · form4.xml · derivative · entry 19

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 128,295 shares

Expires 2027-11-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of October 16, 2017. These options are fully vested.

SEC source: 0001140361-25-037740 · form4.xml · derivative · entry 18

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 977,050

Underlying: Common Stock · 10,307 shares

Expires 2026-03-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options are fully vested.

SEC source: 0001140361-25-037740 · form4.xml · nonDerivative · entry 11

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,504,959

F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.

SEC source: 0001140361-25-037740 · form4.xml · nonDerivative · entry 10

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,643,561

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-25-037740 · form4.xml · nonDerivative · entry 9

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,515,266

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-25-037740 · form4.xml · derivative · entry 17

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,276,523

Underlying: Common Stock · 180,859 shares

Expires 2032-04-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation).

SEC source: 0001140361-25-037740 · form4.xml · derivative · entry 16

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 128,295

Underlying: Common Stock · 107,131 shares

Expires 2027-11-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of October 16, 2017. These options are fully vested.

SEC source: 0001140361-25-037740 · form4.xml · derivative · entry 15

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 987,357

Underlying: Common Stock · 67,171 shares

Expires 2026-03-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of December 27, 2019. These options are fully vested.

SEC source: 0001140361-25-037740 · form4.xml · nonDerivative · entry 8

Venker Eric · CIK 0001801917 · President & Immunovant CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,504,959

F1 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.